Update of the CLRP eye plaque brachytherapy database for photon-emitting sources
Authors:
Habib Safigholi,
Zack Parsons,
Stephen G. Deering,
Rowan M. Thomson
Abstract:
Purpose: To update and extend the Carleton Laboratory for Radiotherapy Physics (CLRP) Eye Plaque (EP) dosimetry database for low-energy photon-emitting brachytherapy sources using egs_brachy, an open-source EGSnrc application. The previous database, CLRP_EPv1, contained datasets for the Collaborative Ocular Melanoma Study (COMS) plaques (2008). The new database, CLRP EPv2, consists of newly-calcul…
▽ More
Purpose: To update and extend the Carleton Laboratory for Radiotherapy Physics (CLRP) Eye Plaque (EP) dosimetry database for low-energy photon-emitting brachytherapy sources using egs_brachy, an open-source EGSnrc application. The previous database, CLRP_EPv1, contained datasets for the Collaborative Ocular Melanoma Study (COMS) plaques (2008). The new database, CLRP EPv2, consists of newly-calculated 3D dose distributions for 17 plaques [8 COMS, 5 Eckert & Ziegler BEBIG, and 4 other representative models] for Pd-103, I-125, and Cs-131 seeds.
Methods: Plaque models are developed with egs_brachy, based on published/manufacturer dimensions and material data. The BEBIG plaques are identical in dimensions to COMS plaques but differ in elemental composition and/or density. Eye plaques and seeds are simulated at the centre of full-scatter water phantoms, scoring in (0.05 cm)^3 voxels spanning the eye for scenarios: (i) HOMO: simulated TG43 conditions; (ii) HETERO: eye plaques and seeds fully modelled; (iii) HETsi (BEBIG only): one seed is active at a time with other seed geometries present but not emitting photons (inactive). For validation, doses are compared to those from CLRP_EPv1 and published data.
Data Format and Access: Data are available at https://physics.carleton.ca/ clrp/eye_plaque_v2, http://doi.org/10.22215/clrp/EPv2. The data consist of 3D dose distributions (text-based EGSnrc 3ddose file) and graphical presentations of the comparisons to previously published data.
Potential Applications: The CLRP EPv2 database provides accurate reference 3D dose distributions to advance ocular brachytherapy dose evaluations. The fully-benchmarked eye plaque models will be freely-distributed with egs brachy, supporting adoption of model-based dose evaluations as recommended by TG-129, TG-186, and TG-221.
△ Less
Submitted 5 February, 2021;
originally announced February 2021.
Dosimetric investigation of 103Pd permanent breast seed implant brachytherapy based on Monte Carlo calculations
Authors:
Stephen G. Deering,
Michelle Hilts,
Deidre Batchelar,
Juanita Crook,
Rowan M. Thomson
Abstract:
PURPOSE: Permanent breast seed implant (PBSI) using 103Pd is emerging as an effective adjuvant radiation technique for early-stage breast cancer. However, clinical dose evaluations follow the water-based TG-43 approach with its considerable approximations. Towards clinical adoption of advanced TG-186 model-based dose evaluations, this study presents a comprehensive investigation for PBSI consideri…
▽ More
PURPOSE: Permanent breast seed implant (PBSI) using 103Pd is emerging as an effective adjuvant radiation technique for early-stage breast cancer. However, clinical dose evaluations follow the water-based TG-43 approach with its considerable approximations. Towards clinical adoption of advanced TG-186 model-based dose evaluations, this study presents a comprehensive investigation for PBSI considering both target and normal tissue doses. METHODS: Dose calculations are performed with the free open-source Monte Carlo (MC) code, egs_brachy, using 2 types of virtual patient models: TG43sim (simulated TG-43 conditions: all water with no interseed attenuation) and MCref (heterogeneous tissue modelling from patient CT, interseed attenuation, seeds at implant angle) for 35 patients. Sensitivity of dose metrics to seed orientation and the threshold for glandular/adipose tissue segmentation are assessed. RESULTS: In the target volume, D90 is 14.1% lower with MCref than with TG43sim, on average. Conversely, normal tissue doses are generally higher with MCref than with TG43sim, e.g., by 22% for skin D1cm2, 82% for ribs Dmax, and 71% for heart D1cm3. Discrepancies between MCref and TG43sim doses vary over the patient cohort, as well as with the tissue and metric considered. Doses are sensitive to the glandular/adipose tissue segmentation threshold with differences of a few percent in target D90. Skin doses are sensitive to seed orientation. CONCLUSIONS: TG-43 dose evaluations generally underestimate doses to critical normal organs/tissues while overestimating target doses. There is considerable variation in MCref and TG43sim on a patient-by-patient basis, suggesting that clinical adoption of patient-specific MC dose calculations is motivated. The MCref framework presented herein provides a consistent modelling approach for clinical implementation of advanced TG-186 dose calculations.
△ Less
Submitted 29 December, 2020;
originally announced December 2020.
